Market open
Acumen Pharmaceuticals/$ABOS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Acumen Pharmaceuticals
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
Ticker
$ABOS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
52
Website
ABOS Metrics
BasicAdvanced
$190M
Market cap
-
P/E ratio
-$1.12
EPS
0.11
Beta
-
Dividend rate
Price and volume
Market cap
$190M
Beta
0.11
52-week high
$5.09
52-week low
$1.81
Average daily volume
198K
Financial strength
Current ratio
17.369
Quick ratio
16.957
Long term debt to equity
12.133
Total debt to equity
12.185
Interest coverage (TTM)
-29.66%
Management effectiveness
Return on assets (TTM)
-20.55%
Return on equity (TTM)
-31.42%
Valuation
Price to book
0.78
Price to tangible book (TTM)
0.78
Price to free cash flow (TTM)
-3.307
Growth
Earnings per share change (TTM)
-2.00%
3-year earnings per share growth (CAGR)
-82.72%
What the Analysts think about ABOS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Acumen Pharmaceuticals stock.
ABOS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ABOS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ABOS News
AllArticlesVideos
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference
GlobeNewsWire·2 days ago
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference
GlobeNewsWire·1 week ago
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Acumen Pharmaceuticals stock?
Acumen Pharmaceuticals (ABOS) has a market cap of $190M as of November 08, 2024.
What is the P/E ratio for Acumen Pharmaceuticals stock?
The price to earnings (P/E) ratio for Acumen Pharmaceuticals (ABOS) stock is 0 as of November 08, 2024.
Does Acumen Pharmaceuticals stock pay dividends?
No, Acumen Pharmaceuticals (ABOS) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Acumen Pharmaceuticals dividend payment date?
Acumen Pharmaceuticals (ABOS) stock does not pay dividends to its shareholders.
What is the beta indicator for Acumen Pharmaceuticals?
Acumen Pharmaceuticals (ABOS) has a beta rating of 0.11. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.